Association Between Topical Calcineurin Inhibitor Use and Keratinocyte Carcinoma Risk Among Adults With Atopic Dermatitis | Zendy

Maryam M. Asgari | Zendy; AiLin Tsai | Zendy; Lyndsay A. Avalos | Zendy; Monica Sokil | Zendy; Charles P. Quesenberry | Zendy

Open Access

Association Between Topical Calcineurin Inhibitor Use and Keratinocyte Carcinoma Risk Among Adults With Atopic Dermatitis

Author(s) -

Maryam M. Asgari,

AiLin Tsai,

Lyndsay A. Avalos,

Monica Sokil,

Charles P. Quesenberry

Publication year - 2020

Publication title -

jama dermatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.128

H-Index - 166

eISSN - 2168-6084

pISSN - 2168-6068

DOI - 10.1001/jamadermatol.2020.2240

Subject(s) - medicine , calcineurin , atopic dermatitis , dermatology , pimecrolimus , keratinocyte , oncology , transplantation , biochemistry , chemistry , in vitro

Topical calcineurin inhibitors (TCIs), primarily used to treat atopic dermatitis (AD), carry a black box label warning users about the potential for increased skin cancer risk. The risk associated with keratinocyte carcinoma (KC), the most common cancer, defined as basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), remains poorly defined because findings from large-scale postmarketing surveillance studies have not been reported.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research